Deoxyuridine suppression studies in bone marrow in primary refractory sideroblastic anemia.
Because unexplained megaloblastic erythroid maturation occurs in patients with primary refractory sideroblastic anemia (PRSA), deoxyuridine (dU) suppression tests using 125I-UdR were performed on bone marrow from five patients with PRSA. All patients had megaloblastic alterations in the marrow erythroid precursors (with normal serum folate and B12 levels) and numerous ringed sideroblasts, and most had marrow iron overload. Results of the dU suppression tests were normal in all five, both with and without incubation with pharmacologic amounts of folate, B12, and pyridoxal phosphate with or without 1-serine. Despite occasional hematologic improvement subsequent to folate, pyridoxine, or pyridoxal phosphate (PLP) administration in some patients with PRSA, normal dU suppression implies that in our group the availability of B12 and folate (and possibly PLP) was not limiting in the utilization of folate for DNA-thymine synthesis. The marrow erythroid maturation defect remains unexplained.
D000328:Adult; D000368:Aged; D000756:Anemia, Sideroblastic / Q000097:blood*; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D003857:Deoxyuridine / Q000378:metabolism*; D005260:Female; D005492:Folic Acid / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D014805:Vitamin B 12 / Q000097:blood
D005492:Folic Acid; D007501:Iron; D014805:Vitamin B 12; D003857:Deoxyuridine